SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp is seeing significant momentum as the SEC eliminates the pattern day trader rule, a move that retail investors believe will drive higher trading volume and brokerage engagement. The community is actively debating the stock's potential for a short squeeze and long-term valuation recovery following the termination of previous dilution-heavy financing agreements.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying following a strategic shift to redomicile in the U.S. and provide PFIC reporting clarity, which effectively neutralized a recent activist short report targeting the company's tax status. The community is actively discussing the stock's potential for a short squeeze and institutional re-rating as investors focus on the company's progress in high-speed optical networking and its pivot toward U.S. domestic corporate governance.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors digest a massive $8 billion order from SK Hynix for next-generation EUV lithography tools, signaling robust long-term demand for AI-driven chip capacity. Community sentiment remains focused on the company's monopolistic position in the semiconductor supply chain, with active discussions weighing this hardware dominance against broader macroeconomic volatility and geopolitical risks affecting the tech sector.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing intense market volatility driven by a massive, high-short-interest squeeze that has retail and institutional traders debating whether the parabolic run is a sustainable breakout or a looming blow-off top. Community discussion is sharply divided between those chasing the exponential price action and others warning of historical parallels to past meme stock crashes, citing concerns over high RSI levels and potential share dilution.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is capturing significant community attention as it secures defense-focused contracts and advances its neutral-atom technology, with investors closely watching for upcoming financial guidance and potential analyst coverage. While community members discuss the stock's volatility and the long-term potential of quantum sensing to disrupt legacy navigation systems, the prevailing sentiment remains focused on the company's competitive position within the evolving quantum computing sector.

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

High Roller Technologies is trending as retail investors aggressively pile into the stock following a definitive agreement with Crypto.com to enter the U.S. prediction market space. The community is sharply divided between those calling for a multi-day short squeeze toward triple-digit valuations and skeptics warning that the stock is a classic pump-and-dump setup prone to rapid volatility.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood (HOOD) is seeing a surge in investor interest driven by a significant regulatory shift following the SEC's approval to eliminate the $25,000 minimum equity requirement for day trading, a move the community believes will lower barriers to entry and increase platform activity. Investors are actively debating the long-term bullish implications of this policy change on revenue and retail participation, while others remain focused on technical levels and broader correlations with crypto market momentum.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is seeing heightened volatility and active community debate as investors speculate on semiconductor demand amidst geopolitical uncertainty, with many traders closely monitoring the impact of potential trade escalations and sector-specific supply chain constraints. Discussions remain sharply divided between those playing for a short squeeze or breakout and those hedging against potential downturns, highlighting the stock's role as a high-beta instrument for both momentum bulls and inverse-focused bears.

Mezo is the onchain Bitcoin banking platform owned by its users. Users can access self-service Bitcoin finance without interacting with loan officers, undergoing credit checks, or observing operational hours. It’s just you, your Bitcoin, and permissionless access to financial services 24/7.  Traditional banks profit from your deposits while charging you for access to your own money. Two-sided lending markets trap you with 8-9% variable rates that can spike unpredictably, especially in decentralized financial systems. Both systems put middlemen between you and your wealth.  Mezo eliminates them all, giving you the power to manage your finances intelligently on your own terms.  Deposit Bitcoin as collateral, mint MUSD (a dollar-pegged stablecoin), and use it however you need. Your Bitcoin stays yours while MUSD provides you with instant liquidity. Fixed rates start as low as 1% and stay fixed for the entire life of the loan.  This is self-service banking with complete autonomy. Unlike any traditional banking experience, there are no minimum payments, set repayment schedules, or penalties for early repayment. Close your position tomorrow or keep it open for years.  It’s your Bitcoin and your decision on what to do with it.

MEZO

MEZO is capturing significant attention as a newly listed Bitcoin side-chain token that offers utility in staking, governance, and DeFi through a strategic partnership with Aerodrome Finance. While some community members are optimistic about its long-term potential within the Bitcoin ecosystem, others are actively debating whether the current price action represents a genuine breakout opportunity or a volatile pump-and-dump scenario.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is gaining momentum as the community highlights its unique 15-year history as the original Bitcoin parody, framing its recent shift to on-chain status as a long-awaited rediscovery. Investors are actively discussing the project's organic growth and the accumulation by whale wallets, with many proponents viewing the current consolidation phase as a strategic opportunity before broader market recognition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week High  - Should You Buy?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week High - Still a Buy...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 6.3% Higher - Still a Buy?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading Up 6.3% - Here's What Happened...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Passes Above Two Hundred Day Moving Average - What's Next?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Pass Above 200 Day Moving Average - Here's What Happened...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8.7% Higher - Time to Buy?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8.7% Higher - Should You Buy...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Passes Above Two Hundred Day Moving Average - Here's Why

Lexicon Pharmaceuticals (NASDAQ:LXRX) Share Price Passes Above 200 Day Moving Average - Should You Sell...

LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug

Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.

Lexicon Pharmaceuticals' (LXRX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated a "buy" rating and issued a $6.00 price objective on shares of Lexicon Pharmaceuticals in a report on Monday...

<ul class="summary-bullets"><li>The start of the trial triggered a second $10 million milestone payment to Lexicon.</li><li>The Phase 1 study will evaluate safety and dosing in 96 overweight or obese participants.</li><li>The trial is expected to be completed in early 2027, Novo said.</li></ul>Novo Nordisk (NVO) is pushing deeper into next-gen obesity treatments. The drugmaker announced on Monday that it has initiated a Phase 1 study of LX9851, Lexicon Pharmaceuticals’ oral non-incretin drug candidate for obesity and related metabolic disorders.&nbsp;This adds to Novo’s obesity treatment pipeline, which also features the semaglutide injection, famously known as Wegovy.&nbsp;At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/NVO">NVO shares</a> climbed 1%, while&nbsp;<a href="https://stocktwits.com/symbol/LXRX">Lexicon Pharmaceuticals’ (LXRX) stock</a> traded over 5% higher.<h2 class="st-heading-2">Novo’s $10 Million Milestone Payment To Lexicon</h2>The start of the trial triggered a second $10 million milestone payment to Lexicon under their licensing deal signed in March 2025. The agreement gives Novo Nordisk exclusive global rights to develop and commercialize the drug, with Lexicon eligible to receive up to $1 billion in total milestone payments, as well as royalties on future sales.The Phase 1 study will evaluate safety and dosing in 96 overweight or obese participants. The trial is expected to be completed in early 2027.“LX9851 offers a novel approach to the treatment of obesity and related metabolic conditions. It is an important addition to our pipeline of potential treatment options as we look to meet the diverse needs of people living with obesity, diabetes and their associated comorbidities,” said Jacob Sten Petersen, Senior Vice President and Head of Global Research at Novo Nordisk.&nbsp;<h2 class="st-heading-2">Lilly’s&nbsp;Experimental Diabetes Pill Outperforms Oral Semaglutide&nbsp;</h2>This comes days after&nbsp;Eli Lilly and Company (LLY) announced that its experimental diabetes pill, Orforglipron, outperformed oral semaglutide in a large Phase 3 study, delivering stronger reductions in blood sugar and greater weight loss over 52 weeks. Lilly has filed the drug for approval in more than 40 countries and plans to submit it in the U.S. later this year.Drug developers are racing to tap the booming obesity market, currently led by injectables like Wegovy and Eli Lilly’s Zepbound.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for NVO and LXRX remained in the ‘bearish’ zone over the past 24 hours.One user called LXRX’s price point “attractive.”<stembedurl>https://stocktwits.com/macrossluvsrobotech/message/648275638</stembedurl>Another user was skeptical about Novo’s forecast.<stembedurl>https://stocktwits.com/Golferhack12/message/648300759</stembedurl>Year-to-date, NVO stock fell 29% while LXRX shares have gained more than 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk Advances Obesity Pipeline With Early-Stage Oral Drug Trial From Lexicon Deal

The trial is part of a licensing deal between Novo and Lexicon that allows Novo to develop and commercialize the drug.

Equity

XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study

Xenon stock soars after phase III X-TOLE2 shows azetukalner significantly cuts focal onset seizure frequency. The company plans an NDA filing in third-quarter 2026.

Citigroup Forecasts Strong Price Appreciation for Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock

Citigroup lifted their price objective on Lexicon Pharmaceuticals from $2.10 to $2.30 and gave the company a "buy" rating in a report on Tuesday...

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Current Price	$1.75
Prev Close	$1.71
Open	$1.70
Dividend Yield	0.00%
50-Day Moving Average	$1.54
Beta	1.61
Avg. Volume	2.85M
PE Ratio	-12.61

52-Week High	$1.84
52-Week Low	$0.48
Market Capitalization	$724.49M
EPS (Annual)	-$0.1387
Price to Book	5.91
Revenue Per Employee	$614,851.85

LXRX
Lexicon Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LXRX News

LXRXLexicon Pharmaceuticals Inc